Telaprevir
- Generic Name
- Telaprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H53N7O6
- CAS Number
- 402957-28-2
- Unique Ingredient Identifier
- 655M5O3W0U
- Background
Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
Telaprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .
- Associated Conditions
- Chronic Hepatitis C Genotype 1
- Associated Therapies
- -
A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir
- Conditions
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Janssen Infectious Diseases BVBA
- Target Recruit Count
- 24
- Registration Number
- NCT01635829
A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Janssen Infectious Diseases BVBA
- Target Recruit Count
- 24
- Registration Number
- NCT01600976
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
- Conditions
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 881
- Registration Number
- NCT01598090
- Locations
- 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT01592006
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT01581138
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 74
- Registration Number
- NCT01571583
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 103
- Registration Number
- NCT01516918
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
- Conditions
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 163
- Registration Number
- NCT01513941
Telaprevir Open-Label Study in Co-Infected Patients
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 122
- Registration Number
- NCT01500616
Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 36
- Registration Number
- NCT01498068
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.